XML 57 R46.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Reconciliation of Adjusted EBITDA to Net Loss | The following table presents our revenue and significant expenses reviewed by our CODM, other segment items and net loss attributable to common shareholders of Evolent Health, Inc. (in thousands):
| For the Three Months Ended September 30, |  | For the Nine Months Ended September 30, |
| 2025 |  | 2024 |  | 2025 |  | 2024 |
Revenue | $ | 479,533 |  |  | $ | 621,401 |  |  | $ | 1,407,510 |  |  | $ | 1,908,199 |  |
Less: |  |  |  |  |  |  |  |
Medical expense and device costs | 274,628 |  |  | 448,596 |  |  | 816,466 |  |  | 1,333,657 |  |
Cost of revenue excluding medical expense and device costs and other segment items (1) | 103,890 |  |  | 90,995 |  |  | 285,466 |  |  | 279,571 |  |
Selling, general and administrative expenses excluding other segment items (2) | 62,060 |  |  | 50,009 |  |  | 192,216 |  |  | 157,123 |  |
Depreciation and amortization expenses | 23,615 |  |  | 29,701 |  |  | 70,814 |  |  | 89,074 |  |
Interest income | (964) |  |  | (794) |  |  | (3,322) |  |  | (4,714) |  |
Interest expense | 16,475 |  |  | 6,010 |  |  | 38,461 |  |  | 18,002 |  |
Gain (loss) from equity method investees | (156) |  |  | 2,229 |  |  | (334) |  |  | 3,623 |  |
Provision from income taxes | 906 |  |  | (619) |  |  | 1,551 |  |  | (292) |  |
Change in tax receivables agreement liability | — |  |  | — |  |  | — |  |  | 173 |  |
Other segment items (3) | 26,009 |  |  | 26,505 |  |  | 156,462 |  |  | 94,821 |  |
Net loss attributable to common shareholders of Evolent Health, Inc. | $ | (26,930) |  |  | $ | (31,231) |  |  | $ | (150,270) |  |  | $ | (62,839) |  |
———————— (1)Other segment items excluded from cost of revenue excluding medical expense and device costs include $1.2 million and $2.9 million of stock compensation for the three and nine months ended September 30, 2025, respectively, and $1.1 million and $3.3 million for the three and nine months ended September 30, 2024, respectively. (2)Other segment items excluded from selling, general and administrative expenses include the following (in thousands):
| For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Stock-based compensation | $ | 13,441 |  |  | $ | 13,299 |  |  | $ | 34,395 |  |  | $ | 42,532 |
Severance costs | 1,540 |  |  | 1,680 |  |  | 3,345 |  |  | 2,860 |
Transaction-related costs | 551 |  |  | 2,072 |  |  | 1,254 |  |  | 2,235 |
Repositioning costs | — |  |  | — |  |  | — |  |  | 10,599 |
(3)Other segment items is defined as stock-based compensation, severance costs, transaction-related costs and repositioning costs not included in cost of revenue or selling, general and administrative expenses calculated in accordance with GAAP, loss on lease termination, change in fair value of contingent consideration, gain on extinguishment of short-term debt, extinguishment of Series A Preferred Stock and other refinancing fees, loss on option exercise, other income (expense), net, and dividends and accretion of Series A Preferred Stock and excise tax on Series A Preferred Stock. Management believes cost of revenue excluding medical expense and device costs and other segment items and selling, general and administrative expenses excluding other segment items are useful to investors because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration